Reporting from: American Society of Hematology Meeting, Philadelphia, December 6-10, 2002 Scientific Editors: George Canellos, Dana-Farber Cancer Institute, Boston Anton Hagenbeek, University of Utrec
Reporting from:
American Society of Hematology Meeting,
Philadelphia, December 6-10, 2002
Scientific Editors:
George Canellos, Dana-Farber Cancer Institute, Boston
Anton Hagenbeek, University of Utrecht
John Goldman, Hammersmith Hospital
Volker Diehl, University of Cologne
Producer: Derek Thorne
Presenters: Derek Thorne & Peter Goodwin
Interviews in this edition:
Proteasome Inhibitor – New Hope for Refractory Myeloma
Paul Richardson, Dana-Farber Cancer Institute, Boston
The conference heard about a phase II trial of the proteasome inhibitor bortezomib. The drug has shown promising results in a group of heavily pre-treated myeloma patients, without excess toxicity.
COMMENT: George Canellos, Dana-Farber Cancer Institute
Fludarabine, Mitoxantrone, Rituximab Remissions in Mantle Cell Lymphoma
Alexandra Levine, USC Norris Cancer Hospital, Los Angeles
With transplants an unlikely option for older patients with mantle cell lymphoma, what else can a doctor do? This study, involving 15 patients, shows that a triple therapy regimen could produce durable responses
COMMENT: George Canellos, Dana-Farber Cancer Institute
Rituximab to Aid Molecular Lymphoma Remission After Transplant?
Wolfram Brugger, University of Tübingen
Although monoclonal antibodies may not be able to eliminate large numbers of lymphoma cells, they could help to mop up the smaller numbers remaining after more drastic cyto-reductive treatments. Rituximab was tested in this way, in follicular and mantle cell lymphoma.
Immunoconjugate Safe So Far in B-Cell Lymphomas
Myron Czuczman, Roswell Park Cancer Institute, Buffalo
Ibritumomab tiuxetan (zevalin), a radiolabelled monoclonal antibody, is currently in use for the treatment of B-cell lymphomas. But some doctors are concerned that it might promote secondary malignancies. ASH delegates heard about its 9 year safety record.
CD22 Monoclonal to Improve B-Cell NHL Responses?
John Leonard, Cornell University, New York
Epratuzumab is a new monoclonal antibody that recognizes the CD22 antigen on malignant cells. This investigation looked at its performance in patients with B-cell non-Hodgkin’s Lymphoma.
Rituximab Responders: Re-Treatment Best in Relapse
Bertrand Coiffier, Hospices Civils de Lyon
What are the options for non-Hodgkin’s Lymphoma patients who respond to rituximab, but eventually relapse? One retrospective analysis suggests the best option is to use rituximab again.
CML: Imatinib Ahead at Molecular Level
Jerry Radich, Fred Hutchinson Cancer Research Centre, Seattle
The IRIS study is the largest and longest randomized study to compare imatinib with interferon and Ara-C. Molecular response data were presented at ASH.
Optimum Imatinib Dose in Accelerated Phase CML
Richard Silver, New York Presbyterian Hospital, New York
The Philadelphia conference heard about imatinib’s performance in accelerated phase CML. The drug’s general activity in these patients has been known for over a year, and new 3 year results can now help doctors to decide on the best dose.
Decitabine Hope for Imatinib Resistance
Jorge Cortes, MD Anderson Cancer Center, Houston
Because of imatinib resistance, additional drugs for CML are currently on the clinical agenda. One is decitabine, an agent that suppresses the methylation of DNA. This drug was recently tested in patients already treated with imatinib.
Immuno Conjugate Potential for AML
Eric Sievers, Fred Hutchinson Cancer Research Center, Seattle
Gemtuzumab ozogamicin (mylotarg), is a new immuno conjugate for AML. According to the most recent studies, it may perform well both alone and in combination with other treatments.
COMMENT: George Canellos, Dana-Farber Cancer Institute
Gene Guided Therapy Soon for Leukemia
Torsten Haferlach, Ludwig-Maximilians University, Munich
Gene profiling, a technique that identifies abnormally expressed genes in malignant cells, may provide accurate and rapid diagnosis of leukemias within a few years, according to a number of investigations presented at ASH.
COMMENT: George Canellos, Dana-Farber Cancer Institute
Related Episodes
Othman Al-Sawaf MD PhD; ASH 2025: Fixed-Duration Targeted Combinations As Effective as Extended Monotherapy for Patients with Untreated Chronic Lymphocytic Leukemia
Othman Al-Sawaf MD PhD, a hematologist from University Hospital of Cologne, presents early data from the CLL17 international phase three trial at ASH 2025. The findings indicate that fixed-duration treatment with venetoclax plus obinutuzumab or venetoclax plus ibrutinib is non-inferior to continuous ibrutinib for patients with previously untreated chronic lymphocytic leukemia, potentially becoming the preferred treatment.
Juan Du MD PhD, ASH 2025: Dual Targeted FasTCAR-T Therapy brings Deep, Durable Responses to Patients with Newly Diagnosed Multiple Myeloma
Dr. Juan Du presented early phase one study findings at ASH 2025, detailing a novel dual-targeted FasTCAR-T therapy for newly diagnosed multiple myeloma. The study demonstrated deep, durable responses in patients using the BCMA and CD19-targeting CAR T-cell platform, GC012F/AZD0120. These promising results, consistent across all dose groups, highlight a highly favorable safety profile and potential for patients, including those with high-risk features and transplant-ineligible individuals.
María-Victoria Mateos; ASH 2025: Unprecedented Survival Benefits with BCMA/CD3 Bispecific Antibody Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma: Majestec-3 Study Findings
This podcast episode, recorded at ASH 2025, features an interview with María-Victoria Mateos MD PhD, who discusses groundbreaking findings from the Majestec-3 study. The study highlights unprecedented survival benefits with the BCMA/CD3 bispecific antibody teclistamab. In patients with relapsed or refractory multiple myeloma, adding teclistamab to standard second-line therapies significantly improved progression-free and overall survival.